Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Other Non-Current Liabilities (2016 - 2025)

Tandem Diabetes Care's Other Non-Current Liabilities history spans 13 years, with the latest figure at $49.7 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 53.67% year-over-year to $49.7 million; the TTM value through Dec 2025 reached $49.7 million, up 53.67%, while the annual FY2025 figure was $49.7 million, 53.67% up from the prior year.
  • Other Non-Current Liabilities reached $49.7 million in Q4 2025 per TNDM's latest filing, down from $52.4 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $52.4 million in Q3 2025 to a low of $116000.0 in Q3 2021.
  • Average Other Non-Current Liabilities over 5 years is $27.8 million, with a median of $26.6 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 99.33% in 2021, then skyrocketed 19752.59% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $17.8 million in 2021, then surged by 34.07% to $23.9 million in 2022, then soared by 33.08% to $31.8 million in 2023, then rose by 1.69% to $32.4 million in 2024, then surged by 53.67% to $49.7 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Other Non-Current Liabilities are $49.7 million (Q4 2025), $52.4 million (Q3 2025), and $52.1 million (Q2 2025).